Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: J Thorac Oncol. 2020 Nov 25;16(3):464–476. doi: 10.1016/j.jtho.2020.11.006

Figure 3:

Figure 3:

a&b) Unsupervised and supervised analysis of the expression of 18 IFN-γ related genes that were previously validated as a pan-tumor T cell-inflamed gene-expression profile (GEP) to predict clinical efficacy of ICB. The normalized expression of this 18-gene panel was relatively higher in carcinoid tumors compared to SCLC but the highest level of expression overall was noted in the SCLC-Y subtype. c&d). Weighted score of the T-cell-inflamed GEP in SCLC showed a higher score in samples from late survivors compared to patient who suffered early deaths while SCLC-Y had the highest GEP score of all the SCLC subtypes.